‘Hitting highs at rock bottom’: LSD treatment for alcoholism, 1950-1970

Dyck presents a historical case study rather than a prospective clinical trial. The extracted text indicates the narrative is built from contemporaneous clinical reports, trial records and published articles from the 1950s and 1960s, as well as correspondence and institutional materials linked to the Saskatchewan research programme and national bodies such as the Addictions Research Foundation (ARF). The author draws on documents produced by investigators (for example, trial transcripts, patient reports and follow-up notes), published trial reports (including Jensen's 1962 controlled trial and ARF publications), and records of interaction with community organisations such as Alcoholics Anonymous. The extracted material does not present a discrete, formal methods section detailing archival repositories, search strategies or selection criteria for sources; however, the text repeatedly cites trial dockets, patient transcripts, local hospital reports and journal debates as primary evidence. Dyck therefore reconstructs events and debates through qualitative historical analysis of primary and secondary sources rather than through systematic meta-analytic or statistical methods.

Dyck recounts the development and clinical practice of LSD therapy in Saskatchewan. Humphry Osmond and Abram Hoffer, drawing on earlier biochemical research into mescaline and schizophrenia, introduced LSD to psychiatric research after moving to Saskatchewan in the early 1950s. Early experiments aimed to elicit powerful experiences that could prompt self-awareness and change in habitual drinkers; initial dosing for alcoholic patients commonly used single doses around 200 micrograms, with some centres later using higher ranges. Clinical programmes varied in setting and procedure. Early trials often placed a patient in a private room with a nurse or psychiatrist, later adding environmental stimuli such as music and visual aids to support the experience. Patients were encouraged to write accounts of their experiences; the Saskatchewan groups emphasised the subjective, often spiritual character of responses and regarded the experience itself as the therapeutic agent rather than the drug alone. Dyck reports that a small early set of patients included one male and one female treated with 200 micrograms: the male remained sober for at least six months, the female initially did not but later stopped during follow-up. The Saskatchewan team later reported trials involving hundreds of patients—claims of similar success with over 700 treated are noted in the narrative. Published trials and follow-up results varied. Colin Smith's 1955/1958 work in Saskatoon involved 24 chronic alcoholics given 200–400 micrograms of LSD; with follow-up from three months to three years, outcomes were described as none worse, 12 unchanged, 6 improved and 6 much improved (the latter defined as complete abstinence during follow-up plus lifestyle change). Institutional documentation included detailed case files: Dyck highlights a set of 216 cases with consent forms, transcripts and patient-written reports that preserved rich subjective material, including vivid first-person accounts of spiritual experiences and insights. Negative or terrifying reactions occurred in a minority of cases; one documented acute distress was terminated medically and yet the patient later judged the experience valuable owing to empathetic staff support. Methodological controversy shaped interpretation of these results. The Addictions Research Foundation criticised the Saskatchewan reports for lack of appropriate controls and for failure to isolate drug effects from environmental and interpersonal influences. Jensen's 1962 comparative study is reported as a controlled, comparative trial with three arms: LSD treatment (58 patients), group therapy (38 patients) and a third group treated by other standard methods (35 patients). Abstinence during follow-up was reported as 38 of 58 in the LSD arm, 7 of 38 in the group-therapy arm and 4 of 35 in the third arm. Conversely, ARF investigators who deliberately minimised environmental support (for example by blindfolding or limiting interaction) reported more limited benefit, concluding that LSD offered no advantage when isolated from supportive context. Other international reports were mixed: a Danish study suggested fear/anxiety sometimes led to sobriety, while a Czechoslovakian study reported positive results in personality disorders. Collectively, the literature recorded both promising outcomes under supportive, context-rich protocols and substantially reduced or absent effects under tightly controlled, interaction-limited conditions. Community engagement and policy effects were prominent findings. Local AA chapters and provincial agencies in Saskatchewan often collaborated with the clinical teams; Bill W., AA's co-founder, experimented briefly with LSD and corresponded with the investigators, and AA chapters sometimes helped recruit patients and provide follow-up. This alliance helped broaden public acceptance of alcoholism as a medical problem and lent political legitimacy to publicly funded treatment programmes. However, by the late 1960s the drug's widespread recreational use and association with countercultural movements, together with the growing primacy of controlled-trial methods in psychopharmacology, undermined clinical and policy support for psychedelic therapy.

Dyck interprets the Saskatchewan LSD programme as a significant episode in the medicalisation of alcoholism, showing how a therapy that foregrounded highly subjective, often spiritual experiences intersected with community organisations and provincial policy to reframe problem drinking as a treatable disease. The account emphasises that supporters—most prominently Osmond and Hoffer—regarded the psychedelic experience itself as central to therapeutic change, and thus sought to integrate biochemical explanations with attention to personal insight and environmental support. This focus resonated with Alcoholics Anonymous principles, creating a medical–communal alliance that strengthened calls for medical treatment rather than moral sanction. At the same time, the paper highlights the methodological tensions that limited psychedelic therapy's acceptance. Critics such as the Addictions Research Foundation insisted on controlled designs that isolated drug effects from environmental and interpersonal influences; trials conducted under such conditions tended to show smaller or no benefits, prompting doubts about the drug's intrinsic efficacy. Dyck notes practical challenges that the Saskatchewan work faced: selection and screening of patients, variable follow-up durations, difficulty in measuring or codifying intensely subjective experiences, and occasional adverse reactions. These limitations, together with the politicised cultural turn of LSD into a recreational emblem of the 1960s, shifted professional and public attitudes. As conventional antipsychotic and antidepressant drugs demonstrated reproducible symptom reduction within controlled-trial frameworks, psychedelic therapy—anchored in a single intense experience and a more philosophical agenda—lost traction within mainstream psychiatry. The author therefore situates the decline of clinical LSD treatments not solely in one cause but as the outcome of intersecting scientific, methodological and social forces: changing standards of evidence in psychopharmacology, criticism from established addiction researchers, difficulties in reconciling subjective experiential effects with objective outcome measures, and wider cultural transformations that eroded the drug's clinical legitimacy. Dyck also points to the policy implications of this history, arguing that the Saskatchewan case helped shape public and administrative understandings of alcoholism and influenced subsequent decisions about treatment priorities.

Dyck concludes that LSD treatment played a prominent—but ultimately transient—role in reframing alcoholism as a medical condition in 1950s Saskatchewan. By producing intense subjective experiences that aligned with AA's spiritual aims and by involving community organisations and provincial authorities, psychedelic therapy strengthened arguments for medical treatment of problem drinking. Nevertheless, methodological critiques, the rise of controlled-trial standards, and the drug's later cultural association with recreational use combined to weaken its clinical standing. The Saskatchewan programme thus illustrates how medical, social and political factors together determine whether a therapeutic approach is institutionalised or sidelined.